Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -76.39 Million SEK | -30.44% |
| 2022 | -58.57 Million SEK | -62.7% |
| 2021 | -35.99 Million SEK | -65.62% |
| 2020 | -21.73 Million SEK | -67.85% |
| 2019 | -12.95 Million SEK | -15.95% |
| 2018 | -11.16 Million SEK | -40.12% |
| 2017 | -7.97 Million SEK | -25.55% |
| 2016 | -6.34 Million SEK | -53.87% |
| 2015 | -4.12 Million SEK | -344.45% |
| 2014 | -928.35 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -6.01 Million SEK | -112.96% |
| 2024 Q1 | -2.82 Million SEK | 94.48% |
| 2023 Q3 | -6.69 Million SEK | 32.73% |
| 2023 Q4 | -51.15 Million SEK | -664.12% |
| 2023 FY | -76.39 Million SEK | -30.44% |
| 2023 Q1 | -8.6 Million SEK | 52.04% |
| 2023 Q2 | -9.95 Million SEK | -15.7% |
| 2022 Q2 | -16.22 Million SEK | -31.16% |
| 2022 FY | -58.57 Million SEK | -62.7% |
| 2022 Q4 | -17.93 Million SEK | -48.92% |
| 2022 Q3 | -12.04 Million SEK | 25.77% |
| 2022 Q1 | -12.37 Million SEK | 5.48% |
| 2021 Q2 | -8.33 Million SEK | -25.02% |
| 2021 Q1 | -6.67 Million SEK | 14.73% |
| 2021 FY | -35.99 Million SEK | -65.62% |
| 2021 Q4 | -13.08 Million SEK | -65.57% |
| 2021 Q3 | -7.9 Million SEK | 5.22% |
| 2020 FY | -21.73 Million SEK | -67.85% |
| 2020 Q1 | -3.52 Million SEK | 33.5% |
| 2020 Q3 | -3.89 Million SEK | 40.04% |
| 2020 Q4 | -7.82 Million SEK | -100.87% |
| 2020 Q2 | -6.49 Million SEK | -84.23% |
| 2019 Q2 | -2.13 Million SEK | 29.2% |
| 2019 Q1 | -3.01 Million SEK | 29.98% |
| 2019 FY | -12.95 Million SEK | -15.95% |
| 2019 Q3 | -2.5 Million SEK | -17.2% |
| 2019 Q4 | -5.3 Million SEK | -111.96% |
| 2018 Q3 | -2 Million SEK | 20.34% |
| 2018 Q1 | -2.33 Million SEK | -4.03% |
| 2018 Q2 | -2.52 Million SEK | -8.05% |
| 2018 Q4 | -4.3 Million SEK | -114.27% |
| 2018 FY | -11.16 Million SEK | -40.12% |
| 2017 Q2 | -2.23 Million SEK | -15.14% |
| 2017 FY | -7.97 Million SEK | -25.55% |
| 2017 Q4 | -2.24 Million SEK | -44.84% |
| 2017 Q3 | -1.54 Million SEK | 30.72% |
| 2017 Q1 | -1.94 Million SEK | 6.89% |
| 2016 Q1 | -1.53 Million SEK | 2.61% |
| 2016 Q2 | -1.38 Million SEK | 9.52% |
| 2016 FY | -6.34 Million SEK | -53.87% |
| 2016 Q4 | -2.08 Million SEK | -55.3% |
| 2016 Q3 | -1.34 Million SEK | 3.17% |
| 2015 Q3 | -1.11 Million SEK | -7.65% |
| 2015 Q1 | -407 Thousand SEK | -341.34% |
| 2015 Q2 | -1.03 Million SEK | -153.81% |
| 2015 Q4 | -1.57 Million SEK | -41.55% |
| 2015 FY | -4.12 Million SEK | -344.45% |
| 2014 Q3 | -383 Thousand SEK | -29.17% |
| 2014 FY | -928.35 Thousand SEK | 0.0% |
| 2014 Q2 | -296.5 Thousand SEK | 0.0% |
| 2014 Q4 | 168.64 Thousand SEK | 144.03% |
| 2014 Q1 | -296.5 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -458.016% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | -105.553% |
| BioGaia AB (publ) | 365.35 Million SEK | 120.911% |
| Enzymatica AB (publ) | -49.72 Million SEK | -53.632% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | -71.246% |
| Gabather AB (publ) | -9.43 Million SEK | -709.558% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | -113.498% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | -262.196% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | -395.93% |
| ODI Pharma AB | 355.97 Thousand SEK | 21561.861% |
| Orexo AB (publ) | -128.3 Million SEK | 40.454% |
| Probi AB (publ) | 16.81 Million SEK | 554.236% |
| Swedencare AB (publ) | 58.6 Million SEK | 230.372% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 103.171% |
| Toleranzia AB | -7.45 Million SEK | -924.239% |
| Vivesto AB | -367.03 Million SEK | 79.185% |